Womens Health Therapeutics, Analysis And Market Forecasts To 2016 – High Unmet Need Will Drive

Womens Health
By BahiaBeauty on 2012-10-16 10:22:39
tags Womens Health Therapeutics, Analysis and Market Forecasts to 2016 – High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets


Women’s Health Therapeutics Market to 2016 – High Unmet Need will Drive the Uptake of Novel Drugs in Menopause and Osteoporosis, provides in-depth analysis of unmet needs, drivers and barriers that impact the global womens health market. The report analyzes the markets for womens health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.


The scope of this report includes:

Annualized market data for the womens health market from 2001 to 2009, forecast forward to 2016.
Analysis of the leading therapeutic segments, including osteoporosis, hormone therapy for menopause, endometriosis, womens infertility and polycistic ovarian syndrome.
Analysis of the womens health market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
Market characterization of the womens health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.
Key drivers and barriers that have a significant impact on the market.
Coverage of pipeline molecules in various phases of drug development.
Competitive benchmarking of leading companies. The key companies studied in this report are Merck, Pfizer, Johnson & Johnson, Teva Pharmaceuticals and Bayer-Schering Pharma.
Key M&A activities, licensing agreements, that have taken place in 2009 in the global blood disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to

Align your product portfolio to the markets with high growth potential.
Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
Develop key strategic initiatives by understanding the key focus areas of leading companies.
Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

For more information, please visit :

Please follow us: